Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.32 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17804259 | 0.92 | BRD9 (0.33) | BRD9BRD7GABRA5GABRG2GABRB3 | |
| SCHEMBL16437199 | 0.91 | FFAR1 (0.35) | BRD9BRD7GABRA5 | |
| SCHEMBL17804246 | 0.91 | GABRA5 (0.35) | MAPTTP53BRD9BRD7GABRA5 | |
| SCHEMBL17811643 | 0.91 | GABRA5 (0.39) | BRD9BRD7GABRA5GABRG2GABRB3 | |
| SCHEMBL17804244 | 0.90 | BRD9 (0.36) | MAPTBRD9BRD7 | |
| SCHEMBL17804248 | 0.88 | CYP11B2 (0.33) | BRD9BRD7GABRA5 | |
| SCHEMBL17811641 | 0.87 | BRD9 (0.34) | MAPTBRD9BRD7GABRA5 | |
| SCHEMBL16206004 | 0.87 | HTR7 (0.33) | MAPTTP53GABRA5 | |
| SCHEMBL17804254 | 0.86 | PDCD1 (0.34) | MAPT | |
| SCHEMBL17796914 | 0.86 | LMNA (0.38) | GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | CYP51A1, CYP4F11, CYP1B1 | MAPT 2890/4885TP53 3929/4885BRD9 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.